| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adaora “Ada” Alise Adimora
|
Venkatesan, Priya
|
|
|
24 |
3 |
p. 235
|
artikel
|
| 2 |
Aleksandra Barac—a global focus on fungal infections
|
Kirby, Tony
|
|
|
24 |
3 |
p. 236
|
artikel
|
| 3 |
Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals
|
Kosugi, Yusuke
|
|
|
24 |
3 |
p. e147-e148
|
artikel
|
| 4 |
Arbovirus research in the Asia-Pacific needs more women in leadership
|
Frentiu, Francesca D
|
|
|
24 |
3 |
p. 231-232
|
artikel
|
| 5 |
A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial
|
Lau, Raphaela I
|
|
|
24 |
3 |
p. 256-265
|
artikel
|
| 6 |
Carissa Etienne
|
Bagcchi, Sanjeet
|
|
|
24 |
3 |
p. 234
|
artikel
|
| 7 |
ChatGPT does not neglect a neglected disease, if appropriately prompted
|
Armitage, Richard
|
|
|
24 |
3 |
p. e155
|
artikel
|
| 8 |
Chronic intestinal schistosomiasis caused by co-infection with Schistosoma intercalatum and Schistosoma mansoni
|
Kołodziej, Przemysław
|
|
|
24 |
3 |
p. e196-e205
|
artikel
|
| 9 |
Climate change recognised in World malaria report 2023
|
Bagcchi, Sanjeet
|
|
|
24 |
3 |
p. e157
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2023; 24: 1
|
|
|
|
24 |
3 |
p. e156
|
artikel
|
| 11 |
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00519-4
|
|
|
|
24 |
3 |
p. e156
|
artikel
|
| 12 |
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2
|
|
|
|
24 |
3 |
p. e156
|
artikel
|
| 13 |
Correction to Lancet Infect Dis 2024; published online Jan 18. https://doi.org/10.1016/S1473-3099(23)00742-9
|
|
|
|
24 |
3 |
p. e156
|
artikel
|
| 14 |
Dengue control, if not by vaccination and vector strategies, then possibly by therapeutics
|
Niranjan, Rituraj
|
|
|
24 |
3 |
p. e144
|
artikel
|
| 15 |
Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study
|
Nkuba-Ndaye, Antoine
|
|
|
24 |
3 |
p. 266-274
|
artikel
|
| 16 |
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
|
Thompson III, George R
|
|
|
24 |
3 |
p. 319-328
|
artikel
|
| 17 |
Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study
|
Barilar, Ivan
|
|
|
24 |
3 |
p. 297-307
|
artikel
|
| 18 |
Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial
|
Wassil, James
|
|
|
24 |
3 |
p. 308-318
|
artikel
|
| 19 |
Gender and geographical representation at infectious diseases and clinical microbiology conferences
|
Last, Katharina
|
|
|
24 |
3 |
p. e153-e154
|
artikel
|
| 20 |
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany
|
Cossmann, Anne
|
|
|
24 |
3 |
p. e145-e146
|
artikel
|
| 21 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
24 |
3 |
p. e163
|
artikel
|
| 22 |
Is it time to reconsider how higher valency pneumococcal conjugate vaccines are evaluated?
|
Temple, Beth
|
|
|
24 |
3 |
p. 228-229
|
artikel
|
| 23 |
Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study
|
Xie, Yan
|
|
|
24 |
3 |
p. 239-255
|
artikel
|
| 24 |
Looking beyond the individual
|
Wortley, Chris
|
|
|
24 |
3 |
p. 238
|
artikel
|
| 25 |
Minimising the threat of bedaquiline-resistant tuberculosis: better diagnosis as prevention
|
Zemanay, Widaad
|
|
|
24 |
3 |
p. 226-228
|
artikel
|
| 26 |
Moxidectin versus ivermectin for strongyloidiasis control
|
Gandasegui, Javier
|
|
|
24 |
3 |
p. e152
|
artikel
|
| 27 |
New antifungals development: rezafungin in candidiasis treatment
|
Desnos-Ollivier, Marie
|
|
|
24 |
3 |
p. 229-231
|
artikel
|
| 28 |
Novel oral polio vaccine for serotype 2: new hope
|
Mathur, Poonam
|
|
|
24 |
3 |
p. 223-224
|
artikel
|
| 29 |
Novel strain of multidrug non-susceptible Neisseria gonorrhoeae in the USA
|
Reimche, Jennifer L
|
|
|
24 |
3 |
p. e149-e151
|
artikel
|
| 30 |
Operational addendum for One Health Joint Plan of Action
|
Jesudason, Timothy
|
|
|
24 |
3 |
p. e158
|
artikel
|
| 31 |
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
|
Gong, Wenping
|
|
|
24 |
3 |
p. 224-226
|
artikel
|
| 32 |
Overcoming publication and dissemination bias in infectious diseases clinical trials
|
Grobusch, Martin P
|
|
|
24 |
3 |
p. e189-e195
|
artikel
|
| 33 |
Peer review at The Lancet Infectious Diseases in 2023
|
Hofer, Ursula
|
|
|
24 |
3 |
p. 232-233
|
artikel
|
| 34 |
Post-acute infection sequelae in focus
|
The Lancet Infectious Diseases,
|
|
|
24 |
3 |
p. 217
|
artikel
|
| 35 |
Post-viral sequelae of COVID-19 and influenza
|
Gandhi, Monica
|
|
|
24 |
3 |
p. 218-219
|
artikel
|
| 36 |
Power and the powerless: COVID-19 impact in southern Africa
|
Ashley-Norman, Phoebe
|
|
|
24 |
3 |
p. 237
|
artikel
|
| 37 |
Preparedness for future outbreaks: strengthening surveillance of survivors of Ebola virus disease
|
Ntoumi, Francine
|
|
|
24 |
3 |
p. 221-223
|
artikel
|
| 38 |
Research in brief
|
Devi, Sharmila
|
|
|
24 |
3 |
p. e164
|
artikel
|
| 39 |
Risk of dengue spread is high globally, says WHO
|
Burki, Talha
|
|
|
24 |
3 |
p. e161-e162
|
artikel
|
| 40 |
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
|
Wajja, Anne
|
|
|
24 |
3 |
p. 285-296
|
artikel
|
| 41 |
Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic
|
Rivera Mejía, Luis
|
|
|
24 |
3 |
p. 275-284
|
artikel
|
| 42 |
Synbiotics in post-acute COVID-19 syndrome—a potential new treatment framework?
|
Raman, Betty
|
|
|
24 |
3 |
p. 219-221
|
artikel
|
| 43 |
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2023
|
The Lancet Infectious Diseases Editors,
|
|
|
24 |
3 |
p. e137-e143
|
artikel
|
| 44 |
The African eye worm: current understanding of the epidemiology, clinical disease, and treatment of loiasis
|
Ramharter, Michael
|
|
|
24 |
3 |
p. e165-e178
|
artikel
|
| 45 |
The next chapter for Africa's genomic initiatives
|
Adepoju, Paul
|
|
|
24 |
3 |
p. e160
|
artikel
|
| 46 |
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry
|
Alosaimy, Sara
|
|
|
24 |
3 |
p. e179-e188
|
artikel
|
| 47 |
UNICEF report reveals gender gaps persist in HIV
|
Das, Manjulika
|
|
|
24 |
3 |
p. e159
|
artikel
|
| 48 |
West Nile meningoencephalitis in infants: look for thalamic involvement
|
Rossillon, Léa
|
|
|
24 |
3 |
p. e206
|
artikel
|
Tijdschrift beschrijving